2. Protein Tyrosine Kinase/RTK
  3. PDGFR
  4. Sennoside B

Sennoside B is a potent and orally active platelet-derived growth factor (PDGF) inhibitor. Sennoside B inhibits cell proliferation and the expression of phosphorylation of PDGFR-β, STAT-5, AKT and ERK induced by PDGF-BB. Sennoside B shows gastroprotective activities. Sennoside B has the potential for the research of gastritis.

For research use only. We do not sell to patients.

Sennoside B Chemical Structure

Sennoside B Chemical Structure

CAS No. : 128-57-4

Size Price Stock Quantity
10 mg USD 25 In-stock
25 mg USD 50 In-stock
50 mg USD 80 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Sennoside B:

Sennoside B Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Sennoside B

View All PDGFR Isoform Specific Products:

View All Isoforms
PDGFR PDGFRβ PDGFRα

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sennoside B is a potent and orally active platelet-derived growth factor (PDGF) inhibitor. Sennoside B inhibits cell proliferation and the expression of phosphorylation of PDGFR-β, STAT-5, AKT and ERK induced by PDGF-BB. Sennoside B shows gastroprotective activities. Sennoside B has the potential for the research of gastritis[1][2].

In Vitro

Sennoside B increases prostaglandin E2 (PGE2) levels and inhibits H+/K+-ATPase[1].
Sennoside B (50, 100 µM) increases the concentration of PGE2 to 105.4 pg/mL and 173.6 pg/mL in AGS gastric cells at doses of 50 μM and 100 μM, respectively[1].
Sennoside B (0, 10, 100, 1000 nM) decreases the expression of PDGF-BB-induced phosphorylation of PDGFR-β, STAT-5, AKT and ERK in a dose-dependent manner[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sennoside B Related Antibodies

Western Blot Analysis[2]

Cell Line: MG63 cells
Concentration: 0, 10, 100, 1000 nM
Incubation Time:
Result: Resulted in a marked inhibition of PDGF-BB-induced PDGFR-β phosphorylation.
In Vivo

Sennoside B (100 mg/kg; p.o.) shows gastroprotective activities by reducing lesion indices in HCl•EtOH and Indomethacin (HY-14397) induces gastritis in rats[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 170-200g, Male Sprague-Dawley rats (HCl•EtOH-induced gastritis)[1]
Dosage: 100 mg/kg
Administration: P.o.
Result: Reduced lesion indices to 60.8 ± 18.4 mm, by inhibition rate of 39.9%.
Molecular Weight

862.74

Formula

C42H38O20
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O[C@@H]1[C@@H](O)[C@H](OC2=C(C(C(C(O)=CC(C(O)=O)=C3)=C3[C@]4([C@@]5(C(C=CC=C6O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)=C6C(C8=C5C=C(C(O)=O)C=C8O)=O)[H])[H])=O)C4=CC=C2)O[C@H](CO)[C@H]1O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (115.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.1591 mL 5.7955 mL 11.5910 mL
5 mM 0.2318 mL 1.1591 mL 2.3182 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.90 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (2.90 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.08%

SDS (393 KB)

COA (261 KB) LCMS (266 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.1591 mL 5.7955 mL 11.5910 mL 28.9774 mL
5 mM 0.2318 mL 1.1591 mL 2.3182 mL 5.7955 mL
10 mM 0.1159 mL 0.5795 mL 1.1591 mL 2.8977 mL
15 mM 0.0773 mL 0.3864 mL 0.7727 mL 1.9318 mL
20 mM 0.0580 mL 0.2898 mL 0.5795 mL 1.4489 mL
25 mM 0.0464 mL 0.2318 mL 0.4636 mL 1.1591 mL
30 mM 0.0386 mL 0.1932 mL 0.3864 mL 0.9659 mL
40 mM 0.0290 mL 0.1449 mL 0.2898 mL 0.7244 mL
50 mM 0.0232 mL 0.1159 mL 0.2318 mL 0.5795 mL
60 mM 0.0193 mL 0.0966 mL 0.1932 mL 0.4830 mL
80 mM 0.0145 mL 0.0724 mL 0.1449 mL 0.3622 mL
100 mM 0.0116 mL 0.0580 mL 0.1159 mL 0.2898 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sennoside B Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sennoside B128-57-4PDGFRPlatelet-derived growth factor receptororally activegastritisgastroprotectivePDGFR-βSTAT-5AKTERKantiproliferationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sennoside B
Cat. No.:
HY-N0366
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.